Publications by authors named "Mark Matijevic"

Claim this Profile
P
Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients With Rheumatoid Arthritis.
Xiaodong Wang, Minggeng Gao, Mark Matijevic, Shauna Quinn, Mason Yamashita

Clin Pharmacol Drug Dev· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD19 and FcγRIIb co-engagement inhibits processes essential to T cell-dependent B-cell responses.
Daniel M Morelli, Heather C Craig, Xiao Feng, Michele Youd, Mark I Matijevic

J Immunol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Pharmacodynamics, Bioavailability, and Immunogenicity of Obexelimab Following Subcutaneous Administration in Healthy Japanese and Non-Japanese Volunteers.
Xiaodong Wang, Rachel Kirk, Mark Matijevic, Minggeng Gao, Allen Poma

Adv Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
Joan T Merrill, Joel Guthridge, Miles Smith, Joshua June, Fotios Koumpouras, Mark Matijevic

Arthritis Rheumatol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder Cancer.
Kuan-Chun Huang, Dinesh Chandra, Shannon McGrath, Vaishali Dixit, Chi Zhang, Mark Matijevic

Mol Cancer Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder Cancer.
Kuan-Chun Huang, Dinesh Chanda, Shannon McGrath, Vaishali Dixit, Chi Zhang, Mark Matijevic

Mol Cancer Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor.
Ruth Plummer, Divyanshu Dua, Nicola Cresti, Yvette Drew, Peter Stephens, Mark Matijevic

Br J Cancer· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer.
Manav Korpal, Xiaoling Puyang, Zhenhua Jeremy Wu, Roland Seiler, Craig Furman, Mark Matijevic

Nat Commun· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer.
Manav Korpal, Xiaoling Puyang, Zhenhua Jeremy Wu, Roland Seiler, Craig Furman, Mark Matijevic

Nat Commun· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.
Makoto Tahara, Martin Schlumberger, Rossella Elisei, Mouhammed Amir Habra, Naomi Kiyota, Mark Matijevic

Eur J Cancer· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point.
Rachel B Darman, Michael Seiler, Anant A Agrawal, Kian H Lim, Shouyong Peng, Mark Matijevic

Cell Rep· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11.
Mark Matijevic, Mary Lynne Hedley, Robert G Urban, Roman M Chicz, Christa Lajoie

Cell Immunol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of interferon-gamma ELISPOT in monitoring immune responses in humans.
Mark Matijevic, Robert G Urban

Methods Mol Biol· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101.
Barbara Klencke, Mark Matijevic, Robert G Urban, Janet L Lathey, Mary Lynne Hedley

Clin Cancer Res· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis